<DOC>
	<DOC>NCT02288325</DOC>
	<brief_summary>This study evaluates the efficacy, safety and tolerability of levomilnacipran extended-release (ER) compared with placebo in the prevention of depression relapse (MDD).</brief_summary>
	<brief_title>A Multicenter, Relapse Prevention Study With Levomilnacipran ER in Patients With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Milnacipran</mesh_term>
	<criteria>Men and Women 1870 Currently meet the DSMV criteria for Major Depressive Disorder (MDD) The patient must have an ongoing major depressive episode of at least 8 weeks and no more than 18 months The patient must have at least 3 lifetime episodes of MDD (including the current episode) Women who are pregnant, women who will be breastfeeding during the study, and women with childbearing potential who are not practicing a reliable method of birth control Patients who are considered a suicide risk History of nonresponse to 2 or more antidepressants (after adequate treatment) Patients who have a history of meeting The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM5) criteria for manic, hypomanic, or mixed episodes schizophrenia or other psychotic disorder obsessivecompulsive disorder Panic disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Fetzima</keyword>
	<keyword>Relapse-prevention</keyword>
	<keyword>Placebo-controlled</keyword>
</DOC>